Immunomodulatory drugs that have been shown to clinically improve IBD symptoms include (1) tumor necrosis factor (TNF) antibodies (infliximab, adalimumab, golimumab), (2) interleukin (IL) 12/23 antibodies (ustekinumab, mirikizumab, guselkumab, risankizumab, brazikumab), (3) integrin antibodies (carotegrast, vedolizumab), and (4) Janus kinase (JAK) inhibitors (tofacitinib, filgotinib, upadacitinib) (Kobayashi and Hibi, 2023; Rogers et al., 2021a). This evidence concerns the gene TNF and inflammatory bowel disease.